Hepatic Encephalopathy Market to Witness Robust Growth, Reaching $2.1 Billion by 2028 As Per The Business Research Company's Hepatic Encephalopathy Global Market Report 2024
March 06, 2024 11:30 ET
|
TBRC Business Research PVT LTD
LONDON, March 06, 2024 (GLOBE NEWSWIRE) -- As per The Business Research Company’s Hepatic Encephalopathy Global Market Report 2024, the global hepatic encephalopathy market, a condition arising from...
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2023
February 29, 2024 16:10 ET
|
GENFIT S.A.
Trésorerie et équivalents de trésorerie : 77,8 millions d’euros au 31 décembre 2023 Chiffre d’affaires : 28,6 millions d’euros au 31 décembre 2023, dont un paiement d’étape de 13,3 millions d’euros...
GENFIT Announces Revenues and Cash Position as of December 31, 2023
February 29, 2024 16:10 ET
|
GENFIT S.A.
Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Upcoming FDA PDUFA...
Ascites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsight
February 21, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ascites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsight The rise in the patient population of ascites, the...
Primary Biliary Cholangitis Pipeline: Insight 2023 Report Highlights Emerging Therapies and Key Players
January 24, 2024 10:51 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis - Pipeline Insight, 2023" report has been added to ResearchAndMarkets.com's offering. A comprehensive analysis entitled...
GENFIT annonce son calendrier financier pour 2024
January 15, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 15 janvier 2024 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans...
GENFIT Announces 2024 Financial Calendar
January 15, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
January 11, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 11 janvier 2024 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans...
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
January 11, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de demandes d’autorisation d’élafibranor dans la Cholangite Biliaire Primitive (PBC)
December 08, 2023 01:55 ET
|
GENFIT S.A.
La Food and Drug Administration (FDA) américaine a accordé un examen prioritaire pour le dépôt du dossier de New Drug Application (NDA) d’élafibranor dans la PBC. L’Agence européenne des médicaments...